In today’s briefing:
- Smartkarma Corporate Webinar | Vividthree: Monetising Content Through Multimedia
- SG Biotech Firm Secures $8.1m at $210m Valuation
- Tencent, SGInnovate Join US$18.1M Series A Round of Horizon Quantum Computing
- Morning Views Asia: China Vanke, Lenovo, Sunny Optical, Times China, Yanlord Land
Smartkarma Corporate Webinar | Vividthree: Monetising Content Through Multimedia
For our next Corporate Webinar, we are glad to welcome Vividthree’s CEO, Jonathan Zhang.
In the upcoming webinar, Jonathan will share a short company presentation after which, he will engage in a fireside chat with Smartkarma Insight Provider, Angus Mackintosh. The Corporate Webinar will include a live Q&A session.
The Corporate Webinar will be hosted on Tuesday, 18 April 2023, 17:00 SGT.
About Vividthree
Headquartered in Singapore with subsidiaries in Malaysia and China, Vividthree Holdings Ltd. specialises in Visual Effects (“VFX”), animation and Virtual Reality (“VR”) for content creation and services across the Digital Entertainment and Out-of-Home Entertainment sectors, as well as collaborations in Meetings, Incentives, Conferences, Exhibitions (“MICE”) projects.
Since its establishment in 2006, Vividthree has secured its position as Singapore’s leading 3D animation and VFX studio with its multi-award-winning track record. In 2017, the Company expanded into the immersive media space with virtual reality (VR) and augmented reality (AR) capabilities. The Vividthree brand of excellence can be found in many works, including Singapore’s box-office-breaking trilogy Ah Boys to Men, SG50 Future of Us Exhibition, NS50 Home Team parade and Train to Busan VR Tour show.
Vividthree has secured the exclusive rights to develop a VR tour show for Peninsula, the sequel to the 2016 Korean box office hit, Train to Busan, as well as acquired the intellectual property rights to the popular webcomic, Silent Horror.
SG Biotech Firm Secures $8.1m at $210m Valuation
- Singapore-based SCG Cell Therapy, a biotech firm, has recently raised US$8.1 million at a valuation over US$210 million, according to VentureCap Insights, which tracks regulatory filings in Singapore.
- The lead backer of the fundraise – which was marked as a series C1 round – was Hong Kong-based Smartech Investment Holdings, pouring about US$3.4 million into SCG Cell Therapy.
- The investment firm has also backed other Singaporean biotech firms such as Biocheetah and Lion TCR.
Tencent, SGInnovate Join US$18.1M Series A Round of Horizon Quantum Computing
- Singapore-based Horizon Quantum Computing has secured US$18.1 million in a Series A investment from Sequoia Capital India, Tencent, SGInnovate, Pappas Capital and Expeditions Fund.
- The investment will allow the startup to strengthen its science and engineering teams to accelerate product development, establish its new engineering centre in Europe, and bring its technology to the market.
- This round takes Horizon Quantum’s total funding to approximately US$21.3 million.
Morning Views Asia: China Vanke, Lenovo, Sunny Optical, Times China, Yanlord Land
Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
